Key facts
- This page summarizes Jan Skvarka's Form 4 filing for Trillium Therapeutics Inc..
- 3 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 19 Nov 2021, 12:20.
Jan Skvarka - 17 Nov 2021 Form 4 Insider Report for Trillium Therapeutics Inc.
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- N/A
- Reported as of
- 17 Nov 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 19 Nov 2021, 12:20:57 UTC
- Prior SEC filing
- 13 May 2021
- Next SEC filing
- 12 Sep 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ James Parsons, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jan Skvarka filed Form 4 for Trillium Therapeutics Inc. on 19 Nov 2021.
Change
- Previous filing in this sequence was filed on 13 May 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TRIL
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- $0
- Shares
- -197,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 17 Nov 2021
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 197,000
- Exercise price
- $0.3000
- Footnotes
- F1, F2
TRIL
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- $0
- Shares
- -1,162,500
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 17 Nov 2021
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 1,162,500
- Exercise price
- $0.4270
- Footnotes
- F1, F3
TRIL
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- $0
- Shares
- -600,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 17 Nov 2021
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 600,000
- Exercise price
- $12.03
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Jan Skvarka is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash.
Footnote F2
The exercise price of these options is $0.38 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD
Footnote F3
The exercise price of these options is $0.54 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD